CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC).
Read MoreSummit Therapeutics Inc. (SMMT) Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. electroCore, Inc. (ECOR) electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. Cassava Sciences, Inc. […]
Read MoreGenie Energy Ltd. (GNE) Genie Energy Ltd., through its subsidiaries, supplies electricity and natural gas to residential and small business customers in the United States and internationally. Daktronics, Inc. (DAKT) Daktronics, Inc. designs, manufactures, and markets electronic display systems and related products for sporting, commercial, and transportation applications in the United States and internationally. Nature’s […]
Read MoreMarket conditions are Bearish in a Bull Market as of 2023-10-30. This means traders and investors should consider trading with a Bearish bias by raising stop levels on winners and selling losers. Aggressive traders should consider buying put options or shorting stocks with 10% or less of their portfolio. The rank of the Bull Market […]
Read More